Akebia Therapeutics (AKBA) Long-Term Investments (2015 - 2018)
Akebia Therapeutics' (AKBA) quarterly Long-Term Investments came in at $245000.0 in Q4 2018, down 99.51% on a QoQ basis from $49.6 million in Q4 2015.
Akebia Therapeutics (AKBA) Long-Term Investments (2015 - 2018) Analysis & Trends
Akebia Therapeutics (AKBA) has 2 years of Long-Term Investments data on file, last reported at $245000.0 in Q4 2018.
- On a quarterly basis, Long-Term Investments changed N/A year-over-year to $245000.0 in Q4 2018; TTM through Dec 2018 was $245000.0, a N/A change from a year earlier, with the FY2018 full-year figure at $245000.0, changed N/A from the prior year.
- Long-Term Investments for Q4 2018 stood at $245000.0, down from $49.6 million in the prior quarter.
- Over the last five years, Long-Term Investments for AKBA reached as high as $51.0 million in Q3 2015 and fell as low as $245000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.32 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 702.35 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Akebia Therapeutics | 325.80 Mn | 163.20 Mn | 41.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 245,000.00 |
| Dec 31, 2015 | 49.60 Mn |
| Sep 30, 2015 | 50.97 Mn |
| Jun 30, 2015 | 38.76 Mn |
| Mar 31, 2015 | 33.10 Mn |